Skip to main content

Table 4 Distribution of antimicrobial resistance in Haemophilus influenzae and Haemophilus parainfluenzae isolates in healthy people and in patients with sarcoidosis

From: Changes in the prevalence and biofilm formation of Haemophilus influenzae and Haemophilus parainfluenzae from the respiratory microbiota of patients with sarcoidosis

   No. (%) of resistant isolates
Species Place of isolation Sxt Te Ctx Caz Sam AmC Am
Healthy people
Haemophilus influenzae (n = 1) Nasopharynx (n = 1) 0 0 0 0 0 0 0
Haemophilus parainfluenzae (n = 65) Nasopharynx (n = 65) 8 (12.3) 4 (6.2) 4 (6.2) 5 (7.7) 3 (4.6) 1 (1.5) 10 (15.4)
Patients with sarcoidosis
Haemophilus influenzae (n = 19) Nasopharynx (n = 6) 1 (16.7) 0 0 0 0 1 (16.7) 0
Sputum (n = 13) 1 (7.7) 2 (15.4) 0 0 0 0 0
Haemophilus parainfluenzae (n = 96) Nasopharynx (n = 47) 10 (21.3) 9 (19.1) 2 (4.3) 3 (6.4) 0 0 6 (12.8)
Sputum (n = 49) 8 (16.3) 6 (12.2) 1 (2.0) 5 (10.2) 0 0 2 (4.1)
  1. Abbreviations: Am ampicillin, AmC amoxycillin/clavulanate, Caz ceftazidime, Ctx cefotaxime, Sam ampicillin-sulbactam, Sxt trimethoprim/sulfametoxazole, Te tetracycline